Form 51-102F3
Material Change Report

1. Name and Address of Company

Resverlogix Corp. (“Resverlogix”)
300, 4820 Richard Road SW
Calgary, AB T3E 6L1

2. Date of Material Change

July 20, 2015

3. News Release

July 21, 2015 via CNW Group

4. Summary of Material Change

Resverlogix closed the previously-announced private placement of 18,870,000 units, each unit (“Unit”) being comprised of one (1) common share and 0.075358 common share purchase warrants, for aggregate proceeds of approximately CAD$50 million, or CAD$2.67 per Unit. Each whole warrant is exercisable into one common share at CAD$2.67 per share for a period of five years.

5. Full Description of Material Change

Resverlogix closed the previously-announced private placement with Shenzhen Hepalink Pharmaceutical Co., Ltd. (“Hepalink”) and Eastern Capital Limited (“Eastern”).

Under the terms of the transaction, Hepalink subscribed for 13,270,000 units, each unit (“Unit”) being comprised of one (1) common share and 0.075358 common share purchase warrants, for aggregate proceeds of approximately CAD$35 million, or CAD$2.67 per Unit. Each whole warrant is exercisable into one common share at CAD$2.67 per share for a period of five years. After giving effect to the transaction, Hepalink holds approximately 12.63% of Resverlogix's common shares. The common shares and warrants issued to Hepalink are subject to a three year lock-up period. Hepalink is also entitled to nominate one mutually agreed representative for election to the board of directors of Resverlogix.

In addition, Eastern subscribed for 5,600,000 Units for aggregate consideration of approximately CAD$15 million, or CAD$2.67 per Unit. After giving effect to the transaction, Eastern holds approximately 19.57% of Resverlogix's common shares.

6. Reliance of subsection 7.1(2) of National Instrument 51-102

N/A

7. Omitted Information

N/A

8. Executive Officer

Brad Cann, Chief Financial Officer
Telephone: (403) 254-9252

9. Date of Report

July 23, 2015